MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label ...

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained ...
BMJ Open

Social support and multifactorial predictors of perinatal depression: insights from a hospital-based cross-sectional survey in Karachi, Pakistan

Objectives This study aimed to estimate the frequency of depression in mothers during the antepartum and postpartum periods ...